Skip to main content
. 2017 Mar 17;12:907–922. doi: 10.2147/COPD.S130482

Figure 4.

Figure 4

Pooled relative risk of annualized rates of (A) moderate and/or severe exacerbations or (B) severe exacerbations, with 95% CIs, for eligible studies comparing approved LABA/LAMA combinations with approved LABA/ICS combinations.

Note: Insufficient data prevented a similar analysis to be conducted versus approved LAMAs.

Abbreviations: CI, confidence interval; ICS, inhaled corticosteroid; FEV1, forced expiratory volume in 1 second; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.